Illumina, Inc. (ILMN) Stock Price & Analysis
Illumina, Inc. (ILMN) fell 1.41% to USD 194.09 as of July 25, 2026 at 01:13 UTC, according to Nexqual real-time market data.
ILMN last closed at USD 196.86; the session ranged USD 191.57–198 on volume of 1,300,912 shares. Market capitalization is $29.37B, with a 52-week range of USD 88–199.14 (NMS). Source: Nexqual, July 25, 2026 at 01:13 UTC.
Key Statistics (as of July 25, 2026 at 01:13 UTC)
| Price | USD 194.09 |
|---|---|
| Change | ▼ 1.41% (down) |
| Previous Close | USD 196.86 |
| Open | USD 198 |
| Day Range | USD 191.57 – 198 |
| 52-Week Range | USD 88 – 199.14 |
| Volume | 1,300,912 shares |
| Market Cap | $29.37B |
| Exchange | NMS |
Technical Analysis (ILMN)
Nexqual's technical model rates ILMN "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:13 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.64 (neutral) |
| vs SMA50 | Above (USD 169.95) |
| MACD | 6.71 (positive) |
Analyst Ratings (ILMN)
Wall Street analysts rate ILMN "Buy" based on 19 analysts, with a mean price target of USD 172.53 (range USD 95–220), per Nexqual as of July 25, 2026 at 01:13 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 19 |
| Mean Target | USD 172.53 |
| High Target | USD 220 |
| Low Target | USD 95 |
| Buy / Hold / Sell | 11 / 5 / 4 |
Earnings (ILMN)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.23 |
| Revenue Estimate | $1.13B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.15 vs est 1.06 ▲ beat |
| 2025-12-31 | USD 1.35 vs est 1.23 ▲ beat |
| 2025-09-30 | USD 1.34 vs est 1.17 ▲ beat |
| 2025-06-30 | USD 1.19 vs est 1.01 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financials & Fundamentals (ILMN)
| Total Revenue | $4.39B |
|---|---|
| Revenue Growth (YoY) | +4.80% |
| Gross Margin | +68.29% |
| Operating Margin | +18.33% |
| Profit Margin | +19.42% |
| ROE | +33.82% |
| Debt / Equity | 95.07 |
| Current Ratio | 1.75 |
| Total Cash | $1.16B |
| Total Debt | $2.54B |
| Free Cash Flow | $845.63M |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financial Health Score (ILMN)
Nexqual rates Illumina, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:13 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 18% |
| Balance Sheet | Mixed — $1.16B cash vs $2.54B debt |
| Cash Flow | Strong — FCF $846M, 19% margin |
| Efficiency | Strong — ROE 34%, ROA 8.7% |
Ownership (ILMN)
| Insider Ownership | +0.20% |
|---|---|
| Institutional Ownership | +107.10% |
| Shares Outstanding | 151.30M |
| Float | 148.03M |
| Short % of Float | +8.17% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Leadership (ILMN)
Illumina, Inc. is led by Ankur Dhingra (age 49), Chief Financial Officer, per Nexqual as of July 25, 2026 at 01:13 UTC.
| Chief Financial Officer | Ankur Dhingra (age 49) |
|---|---|
| Chief Technology Officer | Steven Barnard (age 64) |
| President | Stephanie Campos |
| Chief Strategy & Corporate Development Officer | Jakob Wedel (age 53) |
Major Backers & Investors (ILMN)
Notable institutional backers of Illumina, Inc. include Capital Group, WCM Investment Management, LLC, AQR Capital Management, LLC, according to Nexqual as of July 25, 2026 at 01:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 10.28% |
| WCM Investment Management, LLC | 3.91% |
| AQR Capital Management, LLC | 2.63% |
| Corvex Management LP | 2.53% |
| AMERICAN BALANCED FUND | 2.37% |
| GROWTH FUND OF AMERICA | 2.29% |
| Sessa Capital IM, L.P. | 2.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.66% |
| BlackRock | 16% |
| State Street | 4.25% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
From Illumina, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
- The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
- It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.
- The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
Partnerships
- It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | USD 656.01 | ▲ 0.74% |
| VRTX | Vertex Pharmaceuticals Incorpor | USD 477.36 | ▲ 1.01% |
| BIIB | Biogen Inc. | USD 202.19 | ▲ 2.25% |
| ISRG | Intuitive Surgical, Inc. | USD 337.5 | ▼ 0.94% |
| CRSP | CRISPR Therapeutics AG | USD 46.54 | ▼ 1.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:13 UTC. This page is informational and not investment advice.